It should be noted that both these therapies are primarily symptomatic; they do not directly address the production of the pathogenic factors.
Guillain Barre syndrome is an acute self-limited disease; therefore therapy is needed only for a limited period of time.
There is minimal information on other autoimmune rheumatic diseases.
There was early enthusiasm for PP/PE as a treatment of chronic rheumatic diseases.
Although PP/PE may remove circulating immunoglobulins and immune complexes, their local production may persist unabated.